Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors

This evaluation of the BRAVO “risk engine” found that it was effective at predicting the benefits of SGLT2is on cardiovascular health through improvements in commonly measured risk factors, including HbA1C, systolic blood pressure, and BMI.


Diabetes Care